Vaginal Progesterone Therapy for Endometrial Protection

Primary Indication: Endometrial Protection in Hormone Replacement Therapy

The American College of Obstetricians and Gynecologists recommends vaginal micronized progesterone 200 mg daily for 12-14 days per 28-day cycle as the first-line option for postmenopausal women requiring endometrial protection with hormone replacement therapy, paired with transdermal 17β-estradiol 50-100 μg daily 1
Vaginal micronized progesterone 200 mg daily for 12-14 days per month is the preferred formulation when combined with continuous estrogen therapy in postmenopausal women with an intact uterus, providing proven endometrial protection while avoiding the cardiovascular and thrombotic risks associated with synthetic progestins 1

The Society for Maternal-Fetal Medicine recommends 17-hydroxyprogesterone caproate 250 mg IM weekly over vaginal progesterone for women with prior preterm birth, based on 2012 guidance 2, 3
Vaginal progesterone is not effective for preventing recurrent preterm birth in women with prior spontaneous preterm birth, but is effective for women with sonographic short cervix (<25 mm) without prior preterm birth 2, 3

The American College of Obstetricians and Gynecologists advises against using vaginal progesterone in women with undiagnosed abnormal genital bleeding, known or suspected breast cancer, active or history of venous thromboembolism or arterial thromboembolism, or known liver dysfunction or disease 1

Annual clinical review focusing on compliance, bleeding patterns, and symptom control is recommended for women using vaginal progesterone therapy 1
No routine laboratory monitoring is required unless specific symptoms arise, and dose should be adjusted according to tolerance and wellbeing 1

Vaginal progesterone does not provide contraceptive protection and should not be relied upon to prevent pregnancy, according to the Centers for Disease Control and Prevention (CDC) 4, 5.
Women of reproductive age using vaginal progesterone for menstrual regulation or fertility issues who wish to avoid pregnancy must use additional contraceptive methods such as condoms, as recommended by the CDC 4.
The presence of progesterone therapy does not eliminate the need for barrier protection against sexually transmitted diseases, as stated by the CDC 4, 5.

Sexual activity is generally not restricted in women using vaginal progesterone for short cervix or preterm birth prevention, unless other obstetric contraindications exist, according to the American College of Obstetricians and Gynecologists (ACOG) 6, 7.
The medication's efficacy is not compromised by intercourse when used as directed for preterm birth prevention, as reported by ACOG 6, 7.
No sexual activity restrictions apply for postmenopausal women using vaginal progesterone for endometrial protection with estrogen therapy, as stated by the European Society of Human Reproduction and Embryology (ESHRE) 8.

Do not assume vaginal progesterone provides contraception—it does not prevent pregnancy and additional contraceptive methods are needed if pregnancy is not desired, as warned by the CDC 4, 5.